Trial reportEuropean journal of clinical pharmacology1994
Acrivastine, terfenadine and diphenhydramine effects on driving performance as a function of dose and time after dosing.
Trial report in European journal of clinical pharmacology, 1994. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00916253 (Method of Assessment of Driving Ability in Patients Suffering From Wakefulness Pathologies, Impact of Modafinil Treatment.), which is not on this map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Method of Assessment of Driving Ability in Patients Suffering From Wakefulness Pathologies, Impact of Modafinil Treatment.
Who cites it
19 citing papers in PubMed, 89 citations in OpenAlex.
- Effects of lasmiditan on simulated driving performance: Results of two randomized, blinded, crossover studies with placebo and active controls.Human psychopharmacology · 2020Trial
- The role of P-glycoprotein in CNS antihistamine effects.Psychopharmacology · 2013Trial
- In-car nocturnal blue light exposure improves motorway driving: a randomized controlled trial.PloS one · 2012Trial
- Trial
- The interactive effects of extended wakefulness and low-dose alcohol on simulated driving and vigilance.Sleep · 2007Trial
- Repeated-dose effects of mequitazine, cetirizine and dexchlorpheniramine on driving and psychomotor performance.British journal of clinical pharmacology · 2006Trial
- Driving ability after acute and sub-chronic administration of levocetirizine and diphenhydramine: a randomized, double-blind, placebo-controlled trial.Psychopharmacology · 2003Trial
- Effects of mizolastine and clemastine on actual driving and psychomotor performance in healthy volunteers.European journal of clinical pharmacology · 1994Trial
- Comparing treatment effects of oral THC on simulated and on-the-road driving performance: testing the validity of driving simulator drug research.Psychopharmacology · 2015Article
- On-the-road driving performance and driving-related skills in older untreated insomnia patients and chronic users of hypnotics.Psychopharmacology · 2014Article
- Residual effects of zopiclone 7.5 mg on highway driving performance in insomnia patients and healthy controls: a placebo controlled crossover study.Psychopharmacology · 2014Article
- Effects of alcohol on automated and controlled driving performances.Psychopharmacology · 2014Article
- Effects of stimulant drugs on actual and simulated driving: perspectives from four experimental studies conducted as part of the DRUID research consortium.Psychopharmacology · 2012Article
- What to do with refractory urticaria patients.Current allergy and asthma reports · 2011Review
- Article
- Histamine H1 receptor blockade predominantly impairs sensory processes in human sensorimotor performance.British journal of pharmacology · 2009Article
- Extended driving impairs nocturnal driving performances.PloS one · 2008Article
- Review
- Cognitive impairment in elderly people. Predisposing factors and implications for experimental drug studies.Drugs & aging · 1995Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The study was conducted according to a nine-way, observer- and subject-blind, cross-over design. Its purpose was to compare the single-dose effects of the following drugs on driving performance: acrivastine (8, 16 and 24 mg); the combination of acrivastine (8 mg) with pseudoephedrine (60 mg); terfenadine (60, 120 and 180 mg); diphenhydramine-HCl (50 mg); and placebo. The subjects were 18 healthy female volunteers. Drug effects were assessed in two repetitions of two driving tests (highway driving and car-following) after each treatment. Acrivastine's impairing effects in both driving tests were similarly dose-related. The 8-mg dose had a small, but significant, effect on highway driving in the first trial. The 16-mg and 24-mg doses significantly impaired driving in both tests during the first trial and the 24-mg dose did so again during the second trial. Neither the combination of acrivastine with pseudoephedrine nor terfenadine caused any significant impairment of performance. Diphenhydramine significantly impaired driving in both tests during every trial. In conclusion, the normal therapeutic dose of acrivastine (8 mg) had little effect on driving performance, and virtually none when that dose was given in combination with pseudoephedrine (60 mg). Higher doses of acrivastine severely impaired driving performance. Terfenadine had no significant effect on driving performance after any dose while diphenhydramine strongly impaired every important driving parameter.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.